MYH6
MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog) is a gene that encodes a protein known as N-Myc, which is a member of the Myc family of transcription factors. This gene is located on the short arm of chromosome 2 (2p24.3) and plays a crucial role in cell cycle regulation, apoptosis, and cellular differentiation.
Function[edit | edit source]
The MYCN gene is primarily expressed during embryogenesis and is involved in the regulation of neurodevelopment. The N-Myc protein functions as a transcription factor that binds to specific DNA sequences, thereby regulating the expression of target genes involved in cell proliferation and growth. It is particularly important in the development of the nervous system, where it helps to control the balance between cell proliferation and differentiation.
Clinical Significance[edit | edit source]
MYCN amplification is a well-known marker of poor prognosis in neuroblastoma, a type of cancer that arises from neural crest cells and primarily affects children. Amplification of the MYCN gene leads to overexpression of the N-Myc protein, which drives uncontrolled cell proliferation and tumorigenesis. This genetic alteration is found in approximately 20-25% of neuroblastoma cases and is associated with rapid disease progression and resistance to therapy.
In addition to neuroblastoma, MYCN amplification has been observed in other types of cancer, including medulloblastoma, retinoblastoma, and certain gliomas. The role of MYCN in these cancers is an active area of research, with efforts focused on developing targeted therapies that can inhibit N-Myc function.
Research and Therapeutic Approaches[edit | edit source]
Given the critical role of MYCN in cancer, there is significant interest in developing therapeutic strategies to target N-Myc. Approaches include:
- Small molecule inhibitors: Compounds that directly inhibit the function of N-Myc or its interaction with other proteins.
- RNA interference (RNAi): Techniques to reduce MYCN expression at the mRNA level.
- Immunotherapy: Strategies to target MYCN-expressing cells using the immune system.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD